肝癌介入治疗概论 肝癌经血管治疗的历史 肝癌经血管治疗的分类 肝动脉栓塞的生理基础 肝脏的血管和肿瘤循环 肝癌TACE术前准备 适应症和禁忌症 肝癌经血管内治疗的技术 肝癌经血管介入治疗的并发症 肝癌经血管介入治疗的结果 肝癌介入治疗的联合治疗 肝癌介入治疗的局限性 TACE 随访
返回首页
  • [影像学随访] 肝癌TACE的随访 日期:2022-02-22 23:13:18 点击:99

    TACE术后病人的随访包括临床和影像 BCLC staging and treatment strategy, 2012 Forner, et al. Lancet. 2012 Mar 31;379(9822):1245-55. 为什么说TACE是中期肝癌的标准治疗 *P values refer to cumulative meta-analysis of five and six studies, respecti ...

  • [HAIC技术] HAIC技术 日期:2022-02-13 22:13:20 点击:99

    尽管标准化的HAIC技术是评估HAIC安全性和疗效的重要因素,但HAIC技术的异质性仍然是评价这一技术的争议之一。 许多HAI化疗技术可以通过放置一个输液港-导管系统来进行。 在过去,输液导管是通过剖腹手术植入的,但患者暴露于与剖腹手术和全身麻醉相关的风险。...

  • [肝动脉灌注化疗] 肝癌肝动脉灌注化疗 日期:2022-02-13 19:50:42 点击:99

    肝动脉灌注化疗,Hepatic artery Infusion Chemotherapy,简称HAIC 按肿瘤药物对肿瘤的生物学效应包括 1. 肿瘤对药物的敏感性 2. 肿瘤与药物的接触时间 3. 肿瘤与药物的接触浓度 2020年《中国临床肿瘤学会(CSCO)原发性肝癌诊疗指南》指出以下类型患者推荐...

  • [HAIC单治疗] HAIC 日期:2022-02-10 00:59:23 点击:99

    简介 Hepatic artery infusion chemotherapy (HAIC) is a treatment modality for advanced hepatocellular carcinoma (HCC). 肝动脉输注化疗(HAIC)是治疗晚期肝癌(HCC)的一种治疗方式。 HAIC entails infusing chemotherapeutic agents directly into hepat...

  • [HAIC联合治疗] 基于HAIC的联合治疗 日期:2022-02-10 00:39:13 点击:99

    The following characteristics of HAIC render it a suitable candidate for combination with other antineoplastic agents for advanced HCC: it is associated with fewer systemic adverse events compared with intravenous chemotherapy, and its cyt...

  • [缺乏进行试验的行业激励措施] HAIC研究潜在障碍:缺乏行业激励 日期:2021-12-28 21:43:21 点击:99

    Lack of Industry Incentive for Conducting Trials 开展试验缺乏行业激励 The patents for the main chemotherapeutic agents used in HAIC, including cisplatin, oxaliplatin, 5-FU, and epirubicin, have expired, thus weakening the motivation for th...

  • [缺乏技术标准] HAIC研究潜在障碍:技术标准化不足 日期:2021-12-28 13:45:34 点击:99

    Insufficient Technical Standardization Techniques and protocols for HAIC have yet to be standardized. HAIC的技术和方案尚未标准化。 The efficacy and safety of HAIC depend substantially on the quality of vascular redistribution. HAIC的有效性...

  • [重复导管 vs 动脉港] HAIC研究潜在障碍:重复导管术 vs 药盒置入 日期:2021-12-28 13:34:36 点击:99

    Two different percutaneous arterial access approaches have been used for HAIC: the first approach entails the use of implantable port-catheter systems, and the second approach involves repeated hepatic artery catheterization. 两种不同的经...

  • [多种化疗方案] HAIC研究的潜在障碍:多种化疗方案 日期:2021-12-28 11:54:22 点击:99

    A standard chemotherapy regimen for HAIC has yet to be established, increasing the challenge of interpreting trial results. HAIC的标准化疗方案尚未建立,这增加了解释试验结果的挑战。 Cisplatin and 5-FU were the most commonly used chemotherap...

  • [异质性患者数据] HAIC研究潜在障碍:数据的异质性 日期:2021-12-27 15:27:25 点击:99

    Studies on HAIC have included populations with various degrees of intrahepatic tumor burden, including the possible presence of PVT/EHS. 对HAIC的研究包括了不同程度肝内肿瘤负荷的人群,包括可能存在PVT/EHS。 Studies on patients with PVT who r...

推荐内容
  • 肝癌TACE的随访

    TACE术后病人的随访包括临床和影像 BCLC staging and treatment strategy, 2012 Forne...

  • 栓塞剂的选择

    栓塞治疗作为肿瘤治疗手段之一,被报道应用于全身多处部位的肿瘤。这其中包括肾癌、肺...

  • 肝癌单纯栓塞(TAE)

    单纯肝动脉栓塞的背景 Bland embolisation: Background 肝癌单纯栓塞(Bland emboliza...

  • 索拉菲尼联合TACE治疗中晚期肝癌

    TACE联合索拉菲尼治疗肝癌的原理和背景 索拉菲尼治疗肝癌的原理 Can we treat advance...

  • TACE的结果

    讨论TACE后的结果是一个很艰巨的任务。首先TACE以来总共有20年之多,你讨论哪一个年代...